Alto Neuroscience (NYSE:ANRO) Shares Down 6.9% – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price dropped 6.9% on Wednesday . The company traded as low as $19.78 and last traded at $19.6890. Approximately 101,812 shares traded hands during trading, a decline of 64% from the average daily volume of 286,108 shares. The stock had previously closed at $21.15.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ANRO shares. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Alto Neuroscience in a research note on Wednesday, May 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $35.00 target price on shares of Alto Neuroscience in a research note on Monday, March 16th. JonesTrading decreased their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Finally, Bank of America began coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.25.

Alto Neuroscience Price Performance

The firm has a market capitalization of $691.73 million, a PE ratio of -8.18 and a beta of 1.22. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The firm’s fifty day simple moving average is $22.78 and its 200-day simple moving average is $19.40.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, research analysts forecast that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC increased its stake in Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after purchasing an additional 225,500 shares during the period. Bank of America Corp DE raised its holdings in Alto Neuroscience by 131.5% in the first quarter. Bank of America Corp DE now owns 25,677 shares of the company’s stock valued at $577,000 after acquiring an additional 14,585 shares in the last quarter. Eversept Partners LP acquired a new stake in Alto Neuroscience in the first quarter valued at approximately $2,814,000. The Manufacturers Life Insurance Company acquired a new stake in Alto Neuroscience in the first quarter valued at approximately $534,000. Finally, Quantinno Capital Management LP raised its holdings in Alto Neuroscience by 1.4% in the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after acquiring an additional 490 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.